Sun exposure triggers a rash. Your genes may explain why.

Filaggrin is the protein that scaffolds your skin’s stratum corneum, the outermost dead cell layer that acts as your barrier. It aggregates keratin filaments into a tight, organized matrix. Think of it as the mortar holding bricks together. When filaggrin is functional, water stays trapped inside your skin and UV rays are filtered by a dense, organized structure.

The FLG R501X and 2282del4 variants are loss-of-function mutations carried by roughly 10% of people with European ancestry. These variants truncate the filaggrin protein, leaving your barrier structurally incomplete. Your skin cannot retain hydration and cannot effectively block UV penetration. UV rays reach deeper into living layers, triggering direct cell damage and immune activation.

With FLG variants, your skin feels dry even after moisturizing. Sun exposure causes redness and itching within minutes. Your barrier is leaky at baseline, so any environmental stressor amplifies the effect. You may also notice eczema or cradle cap in infants, because the barrier deficit starts in childhood.

Interleukin-4 is a signaling cytokine that tells naive T-cells to become Th2 cells, the subset responsible for allergic and eczematic responses. When IL4 signaling is amplified, your immune system defaults toward allergic phenotype: it sees harmless antigens as threats and launches mast cell degranulation and IgE production.

IL4 variants, present in roughly 30 to 35% of the population, increase IL4 production or receptor sensitivity. Your immune system is constitutionally biased toward Th2 activation, meaning UV exposure does not just cause skin damage; it triggers an allergic cascade. Mast cells in your skin degranulate, releasing histamine, tryptase, and inflammatory mediators. Your skin flares not just from UV burn but from immune-mediated inflammation.

With IL4 variants, you may also have asthma, allergic rhinitis, or food sensitivities. Sun exposure feels like an allergy attack, not a simple burn. The itching is intense and can last hours. Topical steroids help temporarily, but the underlying immune bias remains.

Interleukin-13 works alongside IL4 to drive Th2 response, but it has a second, more direct effect: it disrupts tight junctions in the skin barrier and reduces filaggrin expression. IL13 essentially tells your skin cells: stop making barrier proteins and start preparing for inflammation. This dual mechanism makes IL13 variants particularly impactful in photosensitivity.

IL13 variants are carried by roughly 30 to 35% of the population and increase IL13 production. You get a double hit: your barrier is actively being dismantled by immune signaling, and your immune system is primed to overreact to UV exposure. The combination is devastating for sun tolerance. Even low-dose UV can trigger significant flares because your barrier is both structurally weak and immunologically amplified.

With IL13 variants, your rash often develops alongside dryness, itching, and a feeling that your skin is fundamentally compromised. You may flare not just from sun but from heat, sweating, or friction. The rash can spread beyond the exposed area because systemic IL13 is driving skin-wide inflammation.

The vitamin D receptor is not just about bone health. VDR is a nuclear receptor that regulates immune tolerance and skin barrier integrity. When VDR function is optimal, vitamin D signaling tells T-regulatory cells to remain calm and tells skin cells to maintain tight junctions. VDR also controls antimicrobial peptide production in skin, which protects against secondary infection in inflamed areas.

VDR BsmI and FokI variants are present in roughly 30 to 50% of the population, depending on ancestry and specific variant. VDR variants reduce the efficiency of vitamin D signaling, meaning your immune system stays more reactive and your barrier repair is less efficient. This is particularly problematic in photosensitivity because UV exposure triggers systemic inflammation, and a compromised VDR means your body cannot mount a strong anti-inflammatory vitamin D response.

With VDR variants, you often have low vitamin D levels despite adequate sun exposure or supplementation. Your skin flares persist longer because your immune system cannot downregulate effectively. You may also notice that winter makes your rash worse, or that geographic location affects flare frequency, because VDR function is vitamin D dependent.

Tumor necrosis factor-alpha is the master inflammatory cytokine. It activates immune cells, increases vascular permeability, and drives systemic inflammation. In skin, TNF amplifies mast cell activation, increases prostaglandin production, and recruits neutrophils. Chronically elevated TNF transforms a mild environmental trigger into a major inflammatory flare.

The TNF -308G>A variant is carried by roughly 30% of the population and increases TNF production. Your baseline inflammatory tone is elevated, meaning UV exposure pushes you over the threshold into visible inflammation more easily than people with the common G allele. You do not need intense sun to flare; even moderate exposure can trigger redness and itching because your TNF system is already primed.

With TNF variants, your rash is often accompanied by systemic symptoms: fatigue, joint achiness, low-grade fever, or brain fog. Your immune system is not just overreacting to UV; it is constitutionally more inflammatory. You may also notice that stress, sleep deprivation, or infection worsen your rash disproportionately because these triggers amplify TNF production.

CTLA4 is an immune checkpoint protein on T-cells that acts like a brake pedal. When CTLA4 engages, it tells T-cells to stop dividing and to stop producing inflammatory cytokines. This is critical for preventing autoimmune activation. CTLA4 function is particularly important in skin, where immune tolerance prevents self-directed attacks on skin cells. Without CTLA4 braking, T-cells remain activated longer and produce more inflammatory mediators.

The CTLA4 +49A>G variant is present in roughly 45% of the population and reduces CTLA4 expression. Your T-cells have a weaker brake, meaning they remain activated longer and mount stronger responses to perceived threats, including UV-triggered damage signals. This makes you susceptible to autoimmune-flavored skin conditions like vitiligo or psoriasis-like photodermatitis. Your immune system does not just overreact to UV; it fails to downregulate after the initial trigger.

With CTLA4 variants, your rash may show patterns of psoriasis or lichen planus-like changes. The inflammation persists for days or weeks after sun exposure, not just hours. You may also have a family history of autoimmune disease, because CTLA4 affects systemic immune tolerance, not just skin.